Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate a
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... WriteResult, a premier provider of ePRO ... University’s School of Public Health and New Haven Farms ... 4 month-long project. The goal of the study was ... with free access to fresh produce and nutrition education ... like high blood pressure, diabetes and weight gain. Patients ...
(Date:3/25/2015)... -- Optimal Research, LLC has been nominated as a ... Clinical Site or Trial Network". This is ... as a nominee in this ViE award category at ... in 2014. The ViE awards were created to honor ... contributions of companies and individuals in the vaccine industry. ...
(Date:3/25/2015)... 2015 Accelovance, a therapeutically focused contract research ... Contract Research Organization" at the upcoming Vaccine Industry Excellence ... This is the eighth consecutive year Accelovance ... winning for "Best Contract Research Organization" in 2009, 2010, ... 2013. "We,re excited to be a finalist ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... organization is devoted to improving healthcare in rural South ... Africa for the welfare of its people, NEW YORK, ... USA LLP, has been named Chairman of the Board of,the American Friends ... Deloitte, to support the critical work of,the AFPT Board, Archbishop Desmond Tutu ...
... genes that confer risk of, common diseases is empowering individuals ... ... Nov. 16 deCODE genetics,(Nasdaq: DCGN ) today announced the launch ... at their own,genome. Through your subscription to deCODEme(TM), you can learn ...
... release is available in German . , ... simple methods for the production of tiny particles with ... regular patterns in two or three dimensions and at ... have countless applications in modern technology, from diagnostic systems ...
Cached Biology Technology:Deloitte Chairman of the Board Sharon L. Allen Named Chairman of the American Friends of the Phelophepa Train 2deCODE Launches deCODEme(TM) 2deCODE Launches deCODEme(TM) 3deCODE Launches deCODEme(TM) 4Two-faced miniatures 2
(Date:3/17/2015)... SAN DIEGO , March 17, 2015 /PRNewswire/ ... and emotion analytics software, today announced general availability ... on-demand web service for the analysis of facial ... they experience advertising, media content, products and services. ... customer attention, engagement and sentiment - as derived ...
(Date:3/12/2015)... , March 12, 2015 IriTech, a ... a member of the Texas Instruments Design Network, announced ... has demonstrated its IriShield USB MK2120U device during ... facility for pension distribution. The iris ... to be marketed in India ...
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... just 60 years for humans to put many freshwater lakes ... recovery may take a thousand years under the best of ... the Proceedings of the National Academy of Sciences (PNAS), University ... study that showed that the buildup of phosphorus in soils ...
... before Europeans brought honey bees (Apis mellifera) to the Americas, ... stingless bees native to tropical forests. Now, colleagues from the ... the Smithsonian Tropical Research Institute (STRI) warn of the imminent ... of ongoing cultural change and habitat loss. , "In our ...
... for drug resistance in HIV-infected patients at the time ... life expectancy, according to an article in the Nov. ... , Resistance to antiretroviral therapy, even in patients ... However, genotype resistance testing, which involves looking for the ...
Cached Biology News:Study shows eutrophic lakes may not recover for a millennium 2Study shows eutrophic lakes may not recover for a millennium 3Mayan stingless bee keeping: Going, going, gone? 2Drug resistance testing in treatment-naive HIV patients is cost-effective 2
... protein assay reagents package is used for determining ... and detergents. The RC DC protein assay is ... for 500 standard assays: 250 ml RC reagent ... alkaline copper tartrate solution, 2 L dilute Folin ...
... modification that plays an important role ... inflammation, cell-to-cell adhesion, and cell signaling. ... based Glycoprotein Isolation Kits, Concanavalin A ... that allow isolation of glycoproteins from ...
... and PowerPac Basic power supply are used for ... Trans-Blot cell accommodates two 7.5 x 10 cm ... electrode assembly, Bio-Ice cooling unit, buffer tank, lid ... PowerPac basic power supply, 100-120 and 220-240 V, ...
... provides the sensitivity and versatility you expect ... photon counting with selected photomultipliers ensure superior ... Equipped with up to 2 reagent injectors ... gene assays as well as other luminescence ...
Biology Products: